An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
/in Glioblastoma, International PublicationsImmunotherapy of diffuse gliomas: biological background, current status and future developments
/in Glioblastoma, International PublicationsDendritic cell therapy of high-grade gliomas
/in Glioblastoma, International Publications, IOZK VeröffentlichungenImmunizing against breast cancer: a new swing for an old sword
/in Breast Cancer, Dendritic Cells, International PublicationsImmunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma
/in Dendritic Cells, International Publications, Malignant MelanomaDendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant MelanomaAbrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine
/in Dendritic Cells, Hyperthermia, International PublicationsEnhanced T-cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells
/in Dendritic Cells, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer